Metformin combined with progesterone improves efficacy and reduces adverse reactions in early endometrial cancer
Abstract
OBJECTIVE: The purpose of this study was to explore the clinical value of metformin combined with progesterone in the treatment of early endometrial cancer (EC). METHODS: A retrospective study was conducted involving 60 patients with early EC. According to the different treatment regimens, the patients were divided into the monotherapy group (n = 29, receiving progesterone monotherapy) and the combined treatment group (n = 31, receiving metformin combined with progesterone therapy). The clinical efficacy, serum tumor marker levels, body mass index, incidence of adverse reactions, and prognosis were compared between the two groups. RESULTS: = 0.004, P = 0.953). CONCLUSION: Metformin combined with progesterone exerts excellent clinical efficacy in the treatment of early EC. It can significantly reduce serum tumor marker levels and BMI, and decrease the occurrence of adverse reactions.
Fields of Study & Subjects
Metabolism
Diabetes
and Cancer
Endometrial and Cervical Cancer Treatments
Cancer Risks and Factors
Publication details
- Journal / source
- American Journal of Translational Research
- Publisher
- e-Century Publishing Corporation
- Volume
- 18
- Issue
- 1
- Pages
- 574–582
- Publication date
- 1 January 2026
- Language
- EN